SCHEMBL5929068

SCHEMBL5929068

CCc1cccc(CC)c1-c1nc(Cl)c(CN2CCN(Cc3ccccc3)C[C@H]2c2ccccc2)n1CCOC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NR1H2 P55055 3/20 0.35
▸ NR1H3 Q13133 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.33
▸ LMNA P02545 2/20 0.33
▸ HTT P42858 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ CYP3A4 P08684 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ APOBEC3A P31941 1/20 0.32
▸ APOBEC3G Q9HC16 1/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ HTR1D P28221 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5929054 1.00 ALDH1A1 (0.38) ALDH1A1L3MBTL1KMT2ANR1H2NR1H3
SCHEMBL5929125 0.85 GAA (0.40) ALDH1A1KMT2ASMN1; SMN2KDM4EHTT
SCHEMBL5928948 0.78 OPRK1 (0.40) ALDH1A1L3MBTL1KMT2AKDM4EPOLB
SCHEMBL5929119 0.76 CYP2A13 (0.43) ALDH1A1L3MBTL1KMT2ASMN1; SMN2KDM4E
SCHEMBL5929387 0.76 SIGMAR1 (0.39) ALDH1A1KMT2ASMN1; SMN2KDM4ESIGMAR1
SCHEMBL5929248 0.76 KDM4E (0.33) ALDH1A1KMT2ASMN1; SMN2KDM4ELMNA
SCHEMBL5929191 0.72 KDM4E (0.52) ALDH1A1KMT2ASMN1; SMN2KDM4EPOLB
SCHEMBL1912823 0.71 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KDM4ECYP3A4HPGD
SCHEMBL6233587 0.70 CACNA2D1 (0.36) ALDH1A1L3MBTL1SMN1; SMN2KDM4EPOLB
SCHEMBL650433 0.69 CRHR1 (0.36) ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060154917-A1 Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators NEUROGEN CORPORATION (US) 2006-07-13 — — US disclosed
WO-2005007087-A2 SUBSTITUTED (HETEROCYCLOALKYL)METHYL AZOLE DERIVATIVES AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2005-01-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154917-A1 Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators C5AR1, C5AR2, C3AR1 ALDH1A1 3884/4885L3MBTL1 4342/4885KMT2A 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback